Semaglutide (the active compound in Ozempic and Wegovy) has dominated the GLP-1 research conversation since 2021. But a newer investigational compound — Retatrutide — has produced clinical trial results that have drawn significant attention from the research community. This article summarizes the published data comparing these two compounds across efficacy, mechanism of action, and trial outcomes.
This page summarizes published clinical research. All Magnolia RL products are for in vitro research use only and are not intended for human use.
What Each Compound Is
Semaglutide is a GLP-1 receptor agonist — it mimics the glucagon-like peptide-1 hormone, which is released by the gut after eating. By activating GLP-1 receptors in the pancreas and brain, semaglutide enhances insulin secretion (when glucose is present) and suppresses appetite. It has been FDA-approved under the brand names Ozempic (diabetes management) and Wegovy (weight management).
Retatrutide (LY3437943) is an investigational compound developed by Eli Lilly. It is a triple agonist — it activates GLP-1 receptors, GIP receptors (glucose-dependent insulinotropic polypeptide), and glucagon receptors simultaneously. No other compound currently in clinical development combines all three of these mechanisms in a single molecule. Retatrutide is not FDA-approved and remains in Phase 3 trials as of 2026.
Mechanism Comparison
| Mechanism | Semaglutide | Retatrutide |
|---|---|---|
| GLP-1 receptor agonism | ✓ | ✓ |
| GIP receptor agonism | ✗ | ✓ |
| Glucagon receptor agonism | ✗ | ✓ |
| Half-life | ~7 days | ~6 days |
| Dosing frequency | Once weekly | Once weekly |
The key differentiator is glucagon receptor activation. Glucagon receptor agonism raises basal metabolic rate and promotes hepatic fat oxidation — processes that are typically suppressed during weight loss as the body attempts to conserve energy. Research suggests this third pathway directly counteracts the metabolic adaptation that limits outcomes with GLP-1-only compounds.
Phase 2 Trial Data
The landmark Phase 2 retatrutide trial was published in the New England Journal of Medicine in 2023 (Jastreboff et al.). The trial enrolled adults with obesity (BMI ≥30) over 48 weeks.
Weight reduction outcomes at 48 weeks:
| Cohort | Average Weight Reduction |
|---|---|
| Placebo | 2.1% |
| Retatrutide 1mg | 8.7% |
| Retatrutide 4mg | 17.3% |
| Retatrutide 8mg | 22.8% |
| Retatrutide 12mg | 24.2% |
For context, semaglutide 2.4mg (Wegovy) produced approximately 14.9% weight reduction in its pivotal STEP 1 trial at 68 weeks.
Key findings:
- 100% of participants on 8mg and 12mg achieved at least 5% weight reduction
- Women on 12mg achieved an average of 29.0% body weight reduction
- HbA1c reductions of 1.3–2.0% were observed in participants with type 2 diabetes
- Liver fat content decreased by more than 80% in high-dose cohorts
Phase 3 Data (2025)
Phase 3 TRIUMPH-4 trial results, reported in 2025, confirmed and extended the Phase 2 findings over 68 weeks:
- Retatrutide 12mg: 28.7% average body weight reduction at 68 weeks
- This compares to semaglutide’s 14.9% and tirzepatide’s approximately 20–22% in their respective pivotal trials
The TRIUMPH-4 data represents the largest average weight reduction reported in any Phase 3 trial of an anti-obesity compound to date.
Side Effect Profile
Both compounds share a similar gastrointestinal side effect profile — nausea, vomiting, and diarrhea — occurring primarily during dose escalation phases. Both trials found that slower escalation schedules significantly reduced the incidence and severity of GI adverse events.
Retatrutide Phase 2 reported no severe hypoglycemia and no serious treatment-related adverse events in participants without diabetes. The safety profile in the published data was described as comparable to GLP-1 agonists when properly titrated.
Cost Comparison
| Compound | Status | Approximate Monthly Cost |
|---|---|---|
| Semaglutide (Wegovy) | FDA-approved | ~$997 without insurance |
| Tirzepatide (Zepbound) | FDA-approved | ~$1,060 without insurance |
| Retatrutide | Investigational (Phase 3) | Not commercially available |
Retatrutide has no approved commercial price as it remains investigational. Research-grade retatrutide for in vitro study is available at a fraction of the cost of approved pharmaceutical GLP-1 compounds.
Where Research Stands in 2026
Eli Lilly’s TRIUMPH Phase 3 program includes multiple ongoing trials. If results continue to confirm Phase 2 findings, regulatory submissions to the FDA could follow in late 2026 or 2027. Commercial availability, if approved, would likely not precede 2027–2028.
The research community has noted significant interest in retatrutide’s triple-receptor mechanism, particularly the glucagon component, as a potential solution to the metabolic plateau seen in long-term GLP-1 agonist protocols.
Research Supply
Magnolia RL carries research-grade retatrutide for in vitro use:
For the full reconstitution and handling protocol, see our Retatrutide Research Protocol → and Reconstitution Guide →
Sources: Jastreboff et al., NEJM 2023 (Phase 2); TRIUMPH-4 Phase 3 data, 2025; STEP 1 semaglutide trial (Wilding et al., NEJM 2021). All Magnolia RL products are for in vitro research use only.